F. Gasparini

45.7k citations

123 papers · 7.8k indexed · 1 hit paper · h-index 50

Cellular and Molecular Neuroscience top 0.1%
- Neuroscience and Neuropharmacology Research 73
- Photoreceptor and optogenetics research 12
Biological Psychiatry top 1%
Cognitive Neuroscience top 1%
- Autism Spectrum Disorder Research 11
Neurology top 2%
- Neuroinflammation and Neurodegeneration Mechanisms 10
Molecular Biology top 1%
- Receptor Mechanisms and Signaling 23
Genetics
- Genetics and Neurodevelopmental Disorders 15
Nuclear and High Energy Physics
- Particle Detector Development and Performance 12
Spectroscopy
- Molecular Sensors and Ion Detection 11

Co-authors: Will Spooren Rainer Kühn Baltazar Gomez‐Mancilla Peter J. Flor Athina Markou Ivo Vranesic Ralf Kühn Thérèse Di Paolo
Cited by: Cellular and Molecular Neuroscience Biological Psychiatry Cognitive Neuroscience
Journals: Neuropharmacology (13 papers)Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment (7 papers)Psychopharmacology (7 papers)
Partner nations: Switzerland Italy United States

In The Last Decade

F. Gasparini

120 papers receiving 7.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by F. Gasparini

Since Specialization

Citations

This map shows the geographic impact of F. Gasparini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Gasparini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Gasparini more than expected).

Fields of papers citing papers by F. Gasparini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Gasparini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Gasparini. The network helps show where F. Gasparini may publish in the future.

Co-authorship network

The 25 scholars most cited alongside F. Gasparini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F. Gasparini Line = papers co-authored together F. Gasparini links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease International Journal of Molecular Sciences ·Rohitash Kumar Bhatia,Philippe Michaud,F. Gasparini,Alexandre Avraméas	2023	11
2	Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease Cell Reports ·Pavrette Magdala,Marilisa Neri,Mario Bernhard,Irena Brzak,Tatjana Schweizer,L Wang,Stefanie Joller,Eva Rivana,結貴森田,Enrica Maiorana,Annick Waldt,Rachel Cuttat,Ulrike Naumann,Caroline Gubser Keller,Guglielmo Roma,Dominik Feuerbach,Derya R. Shimshek,Ulf Neumann,F. Gasparini,Ivan Galimberti	2022	33
3	Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice NeuroImage ·Valerio Zerbi,Marija Markicevic,F. Gasparini,Aileen Schroeter,Markus Rudin,Nicole Wenderoth	2019	18
4	Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity PLoS Pathogens ·Moisés Saúl Mesa Alcocer,Asvin KK Lakkaraju,Amulya Nidhi Shrivastava,谢惠媛,Silvia Sorce,Assunta Senatore,Charles S. Maher,Simone Hornemann,F. Gasparini,Antoine Triller,Adriano Aguzzi	2017	38
5	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome Nature Reviews Drug Discovery ·Elizabeth Berry‐Kravis,Lothar Lindemann,Aia Elise Jønch,George Apostol,Mark F. Bear,Randall L. Carpenter,Jacqueline N. Crawley,Aurore Curie,Vincent des Portes,Farah Hossain,F. Gasparini,Baltazar Gomez‐Mancilla,David Hessl,Eva Loth,Sebastian H. Scharf,Paul P. Wang,Florian von Raison,Randi J. Hagerman,Will Spooren,Sébastien Jacquemont	2017	233
6	Translating Molecular Advances in Fragile X Syndrome Into Therapy The Journal of Clinical Psychiatry ·Randi J. Hagerman,Vincent Desportes,F. Gasparini,Sébastien Jacquemont,Baltazar Gomez‐Mancilla	2014	40
7	Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias Parkinsonism & Related Disorders ·Olivier Rascol,Susan H. Fox,F. Gasparini,Christopher Kenney,Thérèse Di Paolo,Baltazar Gomez‐Mancilla	2014	88
8	The challenges of clinical trials in fragile X syndrome Psychopharmacology ·Sébastien Jacquemont,Elizabeth Berry‐Kravis,Randi J. Hagerman,Florian von Raison,F. Gasparini,George Apostol,Mike Ufer,Vincent des Portes,Baltazar Gomez‐Mancilla	2013	91
9	The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro BMC Medical Genetics ·Elisabetta Tabolacci,Filomena Pirozzi,Baltazar Gomez‐Mancilla,F. Gasparini,Giovanni Neri	2012	14
10	Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice Behavioural Brain Research ·Ilse Gantois,Andreea Pop,Celine de Esch,Ronald A.M. Buijsen,Tine Pooters,Baltazar Gomez‐Mancilla,F. Gasparini,Ben A. Oostra,Rudi D’Hooge,Rob Willemsen	2012	78
11	Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias Neuroscience ·Bazoumana Ouattara,Daniël Hoyer,Laurent Grégoire,Marc Morissette,F. Gasparini,Baltazar Gomez‐Mancilla,Thérèse Di Paolo	2010	41
12	BLOCKADE OF THE METABOTROPIC GLUTAMATE RECEPTOR MGLUR5 DOES NOT AFFECT NEUROVASCULAR COUPLING IN ADULT SPRAGUE-DAWLEY RATS UCL Discovery (University College London) ·Rain R. Chen,Renaud Jolivet,(unknown),Matthew W. Voorhees,F. Gasparini,Andreas K. Buck,Benjamin Weber	2009	1
13	Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2′-phosphono-3′-phenylcyclopropyl)glycine, the first class of 3′-substituted transC1′−2′-2-(2′-phosphonocyclopropyl)glycines Bioorganic & Medicinal Chemistry ·Maura Marinozzi,Michaela Serpi,Laura Amori,Mónica Díaz‐Gavilán,Gabriele Costantino,Udo Meyer,Peter J. Flor,F. Gasparini,Roland Heckendorn,Rainer Kühn,Gianluca Giorgi,Mette B. Hermit,C. Thomsen,Roberto Pellicciari	2007	12
14	ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies Bioorganic & Medicinal Chemistry ·Samuel Hintermann,Ivo Vranesic,Hans Allgeier,I. Emmanuel,Daniël Hoyer,Michel Lemaire,A. Ewert,Stephan Urwyler,Steven Whitebread,F. Gasparini,Yves P. Auberson	2006	55
15	Group II Metabotropic and α-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate (AMPA)/Kainate Glutamate Receptors Regulate the Deficit in Brain Reward Function Associated with Nicotine Withdrawal in Rats Journal of Pharmacology and Experimental Therapeutics ·Paul J. Kenny,F. Gasparini,Athina Markou	2003	117
16	Neuroprotective Activity of Metabotropic Glutamate Receptor Ligands Advances in experimental medicine and biology ·Peter J. Flor,Giuseppe Battaglia,Ferdinando Nicoletti,F. Gasparini,Valeria Bruno	2003	70
17	[3H]-M-MPEP, a Potent, Subtype-Selective Radioligand for the Metabotropic Glutamate Receptor Subtype 5 Bioorganic & Medicinal Chemistry Letters ·F. Gasparini,Hendrik Andres,Peter J. Flor,Micheline Heinrich,Werner Inderbitzin,Kurt Lingenhöhl,Hans‐Peter Müller,Veronica C. Munk,Kyla Omilusik,Kazuhisa Kobashi,Natacha Stoehr,Ivo Vranesic,Rainer Kühn	2002	63
18	In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: Review article Amino Acids ·Ralf Kühn,Pete Dinham,Natacha Stoehr,Ivo Vranesic,Peter J. Flor,Kurt Lingenhöhl,Will Spooren,C. Gentsch,A. Vassout,Andrzej Pilc,F. Gasparini	2002	40
19	Glutamate release inhibiting properties of the novel mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence Neuropharmacology ·Lisa Thomas,David E. Jane,F. Gasparini,Martin J. Croucher	2001	46
20	Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes Neuropharmacology ·Thomas Knöpfel,Snežana Lukić,M. Louis Olivier,Peter J. Flor,Ralf Kühn,F. Gasparini	1995	43

About F. Gasparini

F. Gasparini is a scholar working on Cellular and Molecular Neuroscience, Neurology and Cognitive Neuroscience, having authored 123 papers that have together received 7.8k indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (73 papers), Receptor Mechanisms and Signaling (23 papers), Genetics and Neurodevelopmental Disorders (15 papers), Photoreceptor and optogenetics research (12 papers), Particle Detector Development and Performance (12 papers), Molecular Sensors and Ion Detection (11 papers), Autism Spectrum Disorder Research (11 papers) and Neuroinflammation and Neurodegeneration Mechanisms (10 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (5.7k citations), Biological Psychiatry (308 citations) and Cognitive Neuroscience (1.5k citations). F. Gasparini has collaborated with scholars based in Switzerland, Italy and United States. Frequent co-authors include Will Spooren, Rainer Kühn, Baltazar Gomez‐Mancilla, Peter J. Flor, Athina Markou, Ivo Vranesic, Ralf Kühn, Thérèse Di Paolo, Natacha Stoehr and Paul J. Kenny. Their work appears in journals such as Neuropharmacology, Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment, Psychopharmacology, Bioorganic & Medicinal Chemistry Letters and Behavioural Brain Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact